Randomized Trialhigh evidence
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Nature medicine·June 7, 2026·PMID 42252333
Why it mattersSurvodutide, a dual glucagon/GLP-1 receptor agonist, offers a novel approach for patients with obesity and MASLD, addressing both liver fat and weight loss in a single agent. This trial provides robust phase 3 evidence of efficacy on liver fat reduction, a key surrogate for MASH improvement.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled